APOB and non-small cell lung carcinoma: Our research suggested that BMI ≥25 kg/m2 and elevated levels of cholesterol‐rich apoB‐containing lipoproteins, including LDL‐C and RC, might be attributed to poor therapeutic response to ICIs‐based therapy, particular in advanced NSCLC patients treated with chemotherapy and ICIs combination.